North America SGLT2 Inhibitors Market Size Worth USD 16.37 Billion by 2034 | CAGR: 8.4%

The North America SGLT2 inhibitors market size is expected to reach USD 16.37 billion by 2034, according to a new study by Polaris Market Research. The report “North America SGLT2 Inhibitors Market Share, Size, Trends, Industry Analysis Report: By Indication [Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others], Drug, Distribution Channel, and Country; Segment Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of type 2 diabetes has led to a substantial demand for effective treatments. Lifestyle factors such as poor diet, sedentary behavior, and rising obesity rates have contributed to the rising number of disease cases, highlighting the need for advanced therapeutic options.

SGLT2 inhibitors, presented by leading drugs such as Jardiance (Empagliflozin), have garnered widespread acceptance due to their dual benefits. These medications effectively manage blood glucose levels and offer significant cardiovascular and renal protection. Clinical trials have demonstrated that SGLT2 inhibitors reduce the risk of major cardiovascular events, heart failure hospitalization, and the progression of chronic kidney disease, making them preferred options for healthcare providers.

Regulatory approvals, notably from the US Food and Drug Administration (FDA) and other regulatory bodies, have played a pivotal role in expanding the market. SGLT2 inhibitors have been approved for multiple indications, including heart failure and chronic kidney disease, beyond their primary use for glycemic control in type 2 diabetes. This expanded therapeutic scope has significantly increased their adoption. Increasing awareness among healthcare providers and patients about the benefits of SGLT2 inhibitors is leading to their increased acceptance and use. Additionally, ongoing research and development have led to the introduction of new SGLT2 inhibitors and combination therapies, further driving the North America SGLT2 inhibitors market expansion.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/north-america-sglt2-inhibitors-market/request-for-sample

The advanced healthcare infrastructure in North America, characterized by well-established healthcare systems and advanced medical facilities, has facilitated the widespread use of these medications. Favorable insurance coverage and reimbursement policies have made SGLT2 inhibitors more accessible to patients, reducing financial barriers to treatment.

Top of FormNorth America SGLT2 Inhibitors Market Report Highlights

• By drug, in 2024, the Jardiance (Empagliflozin) segment accounted for the largest revenue share of the North America SGLT2 inhibitors market. Jardiance's robust clinical profile demonstrates significant benefits in reducing cardiovascular mortality and heart failure hospitalizations, making it a preferred choice for managing type 2 diabetes and associated cardiovascular risks.
• The type 2 diabetes segment, based on indication, is expected to register the highest CAGR during the forecast period. Governments and healthcare organizations in North America implement policies and programs aimed at diabetes prevention, education, and treatment.
• In 2024, the US accounted for a larger share of the North America SGLT2 inhibitors market. Pharmaceutical companies in the country invest significantly in research and development (R&D) to enhance the efficacy, safety, and usability of SGLT2 inhibitors.
• A few key market players are AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and  Pfizer Inc.

Polaris Market Research has segmented the North America SGLT2 inhibitors market report on the basis of indication, drug, distribution channel, and country:

By Indication Outlook (Revenue – USD Billion, 2020–2034)

• Cardiovascular
• Chronic Kidney Disease (CKD)
• Type 2 Diabetes
• Others

By Drug Outlook (Revenue – USD Billion, 2020–2034)

• Farxiga (Dapagliflozin)
• Inpefa (Sotagliflozin)
• Invokana (Canagliflozin)
• Jardiance (Empagliflozin)
• Qtern (Dapagliflozin/Saxagliptin)
• Other SGLT2 Inhibitors

By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies      

    By Country Outlook (Revenue – USD Billion, 2020–2034)

• US
• Canada

North America SGLT2 Inhibitors Market Report Scope